Melatonin: What the Science Actually Shows About Sleep, Timing & Supplementation.
Melatonin is not a sedative. It is a timing signal, and the gap between how people use it and what controlled evidence supports is now a public health problem. Here is what the science actually says, and what to do with it.
01The 1958 Discovery
Melatonin is a timing signal, not a sedative
In 1958, a dermatologist named Aaron Lerner spent four years grinding up 250,000 bovine pineal glands to isolate a single compound he believed would lighten skin pigment.[7] He was wrong about the skin. The molecule he extracted, melatonin, turned out to be something far more consequential: the chemical sentence the human body uses to tell itself what time it is. Nearly seven decades later, that sentence has become the best-selling supplement on American pharmacy shelves, taken nightly by millions of people who believe they are buying sleep.[7] Most of them are buying the wrong thing.
The numbers are worth sitting with. Between 1999 and 2018, US adult melatonin use quintupled, from 0.4% to 2.1% of the adult population, while high-dose use (above 5 mg per day) tripled.[1] By 2023, nearly one in five American children aged 10 to 13 were being given melatonin every month, with a median continuous use duration of 21 months, in a population for which no long-term paediatric safety data exists.[2] Poison control calls for unsupervised paediatric melatonin ingestion rose 530% between 2012 and 2021, from 8,337 to 52,563 cases, with gummy formulations accounting for 47% of exposures.[41][3]
The disconnect is not about whether melatonin works. It does. The disconnect is about what melatonin actually is. The controlled evidence, drawn from 34 peer-reviewed sources including Cochrane reviews, forced-desynchrony protocols, and the largest independent meta-analysis of melatonin for primary sleep disorders, converges on a conclusion most consumers would find surprising: melatonin is a mediocre hypnotic but a remarkably effective chronobiotic, a molecule whose primary clinical value is shifting the timing of the body's internal clock, not sedating the brain into unconsciousness.[21]
That reframe is not semantic. When you understand melatonin as a timing signal rather than a sedative, several problems with typical use become clear. The dose most people take is wrong: pharmacological doses of 3 to 10 mg overwhelm receptor sensitivity without improving sleep outcomes beyond what a physiological dose of 0.5 mg achieves.[25] The timing most people use is also wrong. And the environment most people sleep in actively destroys the signal they are trying to supplement: ordinary room light at 200 lux suppresses endogenous melatonin production by more than 50%.[14]
The result is a strange public health situation. Millions of people take a clock-setting hormone at the wrong time, in the wrong dose, in a light environment that simultaneously erases the signal they are trying to boost. And because melatonin is classified as a dietary supplement in the United States, exempt from the manufacturing controls applied to pharmaceuticals, 71% of over-the-counter products contain a dose that deviates by more than 10% from what the label claims, with some lots varying by up to 465%.[37]
This article traces what the science actually shows, from the molecular pathway that produces melatonin to the controlled human evidence that reveals its real clinical utility. The argument is not that melatonin is useless. The argument is that melatonin is misunderstood, and that understanding it correctly changes what you do with it.
02The Mechanism
The Signal Chain That Turns Darkness Into a Hormone
The story begins behind your eyes. A specialised class of retinal cells, intrinsically photosensitive retinal ganglion cells (ipRGCs) containing the photopigment melanopsin, detects ambient light intensity and transmits that signal directly to the brain's master clock via a process called photoentrainment.[15] These cells are not the ones you see with. They are the ones that tell your body whether it is day or night. Their peak sensitivity falls at 460 to 480 nanometres, the blue end of the visible spectrum, which is why short-wavelength light resets the circadian phase and suppresses melatonin approximately twice as powerfully as green light of the same intensity: a three-hour phase shift versus 1.5 hours in Lockley's controlled comparison.[15]
The signal travels via the retinohypothalamic tract to the suprachiasmatic nucleus (SCN), a cluster of approximately 20,000 neurons in the anterior hypothalamus that functions as the body's master pacemaker.[8][19] The SCN does not produce melatonin. It gates its production. During daylight hours, GABAergic inhibition from the SCN suppresses the sympathetic pathway that would otherwise activate the pineal gland.[19] When darkness arrives and that inhibition lifts, the sympathetic nervous system sends a noradrenergic signal to the pineal, activating the rate-limiting enzyme arylalkylamine N-acetyltransferase (AANAT) and initiating the conversion of serotonin into melatonin.[9]
The biosynthetic pathway is a four-step biochemical cascade: tryptophan → 5-HTP → serotonin → N-acetylserotonin (via AANAT) → melatonin (via HIOMT).[9] The entire process is light-gated. Any significant light exposure during the synthesis window qualifies as a disruptor. Gooley's controlled crossover in 116 subjects demonstrated that 200 lux of ordinary room light delays melatonin onset by approximately 1.5 hours and compresses the total duration of the biological night by 90 minutes.[14]
The retinohypothalamic relay from melanopsin-bearing ganglion cells through the suprachiasmatic nucleus to the pineal, and from the pineal into the bloodstream as a circulating clock signal.
Diagram · HPC
Once synthesised, melatonin broadcasts its timing signal through two G-protein-coupled receptor subtypes distributed across nearly every tissue in the body. MT1 receptors primarily regulate REM sleep architecture and acute melatonin signalling. MT2 receptors selectively promote non-REM sleep onset and mediate the circadian phase-shifting that represents melatonin's most clinically significant action.[10] Both receptor types couple through the inhibitory G-protein (Gi) to reduce intracellular cyclic AMP, creating a sleep-permissive state: a lowering of arousal threshold rather than a pharmacological knock-out.[10][11]
That distinction matters. A sedative like zolpidem forces sleep by amplifying GABA-A receptor activity. Melatonin does not force anything. It tells the body's peripheral clocks, in the liver, pancreas, immune system, and cardiovascular tissue, that night has arrived and that it is safe to shift into nocturnal metabolic programming.[8][17][18] Each of these organs contains its own autonomous clock gene network (CLOCK, BMAL1, PER, CRY), and the melatonin signal synchronises these peripheral oscillators to SCN time, a process called internal synchronisation.[8] When the signal is absent or mistimed, peripheral clocks drift, running on different schedules from each other and from the master pacemaker.
The critical timing marker is dim-light melatonin onset (DLMO), validated by Voultsios and colleagues as occurring approximately two hours before habitual sleep onset.[12] DLMO is the circadian system's version of a starting gun. It marks the moment the body begins its nightly transition from daytime catabolism to nighttime repair and immune surveillance. When melatonin supplementation is timed relative to DLMO rather than clock time, its phase-shifting potency increases substantially, a principle codified in Lewy's phase-response curve (PRC), which shows that evening doses advance the clock while morning doses delay it.[13]
03Evidence
The Five Strongest Studies on Melatonin, Timing & Sleep
01The claim
The single load-bearing finding
The hero study finds >50 % suppression.
Not all melatonin research is equal, and not all of it deserves equal weight in clinical decision-making. The field spans thousands of papers, from animal models and in vitro receptor studies to large-scale epidemiological cohorts and Cochrane systematic reviews. Ranking them requires a framework that distinguishes controlled experimental evidence from observational association, and methodological rigour from sample size alone.
Pooled estimate
>50% suppression
02How we measured
Grading the melatonin trials
Studies scored on design, sample, rigour, causality, replication, citations.
For melatonin research, the critical methodological fault line is distinguishing sleep onset latency from genuine circadian phase advance, two outcomes that require different study designs and make most pooled meta-analyses harder to interpret than their headlines suggest.
Rubric weights
03The spread
Heterogeneity across 5 studies
Methodological quality across the ranked studies.
The gap between the independent meta-analytic estimate (−7.06 minutes) and the industry-sponsored Circadin trial (−24.3 minutes) deserves attention.[21][24] Wade and colleagues' 2007 study was funded by Neurim Pharmaceuticals, the company that manufactures and markets prolonged-release melatonin under the Circadin brand. Its effect size is more than three times larger than the independent pooled estimate.
Rubric spread
88 → 59 /100
Highest to lowest rubric score across the ranked studies.
04What does not hold
Negative knowledge
What the evidence base does not support.
What the hierarchy reveals, taken as a whole, is a molecule whose reputation has outpaced its evidence for one application (sedation) while lagging behind its evidence for another (chronobiotic phase-shifting). The Cochrane jet lag data, the DLMO-confirmed DSPD trial, and the phase-response curve research all point in the same direction: melatonin's strength is in moving the clock, not in forcing sleep. Cruz-Sanabria's dose-response analysis adds the practical specification.
5 trials. One pooled answer.
Below: the anchor study in full; then the forest plot at scale; then the supporting trials in ranked order.
01Anchor
Exposure to Room Light before Bedtime Suppresses Melatonin Onset and Shortens Melatonin Duration in Humans
Standard household lighting is sufficient to halve melatonin production, no screens or blue-light devices required.
Highest causal clarity of any melatonin study: within-subjects design, IV plasma sampling, modifiable environmental exposure isolated without interpretive assumptions. Replicated by Lockley (2003) and West (2011).
Rubric breakdown
The strongest studies, ranked by methodological weight.
Each scored 0–100 against a six-criterion rubric, tagged by design and year; the anchor leads. No study in this set reaches the rubric-90 tier.
02
Efficacy of Melatonin with Behavioural Sleep-Wake Scheduling for Delayed Sleep-Wake Phase Disorder
Low-dose melatonin (0.5 mg) advanced DLMO by 1.18 hours versus 0.26 hours for placebo (p < 0.001); wake time advanced by 34 minutes versus 5 minutes for placebo.[20]
84/100
03
Meta-Analysis: Melatonin for the Treatment of Primary Sleep Disorders
Sleep onset latency reduced by a conservative estimate of 7.06 minutes (95% CI: −9.75, −4.37; fixed-effects primary analysis); total sleep time increased by 8.25 minutes; effects did not dissipate with continued use.[21]
79/100
04
Melatonin for the Prevention and Treatment of Jet Lag (Cochrane Review)
Eight of ten randomised trials showed melatonin effective for jet lag when crossing five or more time zones; 0.5 to 5 mg doses equally effective; timing at destination bedtime (22:00–midnight local) was the critical variable.[22]
74/100
05
Optimizing the Time and Dose of Melatonin as a Sleep-Promoting Drug
Dose-response modelling identified 4 mg as the optimal dose with a plateau above that threshold; administration 3 hours before bedtime significantly outperformed the standard 30-minute-before-bed protocol.[26]
59/100
04Stakes
The downstream cost of a disrupted melatonin signal across four biological systems
When the timing signal is absent or misaligned, the consequences extend far beyond poor sleep, into metabolism, cardiovascular function, immune regulation, and long-term disease risk.
Cardiometabolic Disruption
In a small but highly controlled laboratory study (N=10), Scheer's forced desynchrony protocol demonstrated that circadian misalignment, independent of sleep loss, caused leptin to drop 17%, fasting glucose to rise 6% despite a 22% insulin increase, and mean arterial pressure to rise 3 mmHg.[27] These metabolic markers shifted within days, not months. Leproult's parallel RCT in men (N=26) confirmed that misalignment doubled insulin resistance markers and hsCRP inflammation versus aligned controls with identical total sleep time.[28]
unexplained hunger despite adequate calories, afternoon energy crashes, elevated fasting glucose on routine labs
Heart and Vascular Load
Morris and colleagues demonstrated that just three days of 12-hour behavioural inversion raised systolic blood pressure by 3.0 mmHg and diastolic by 1.5 mmHg in healthy adults.[29] In a small controlled study (N=20), Mason found that a single night of 100-lux bedroom light increased nighttime heart rate, decreased heart rate variability, and produced measurable next-morning insulin resistance.[30]
resting heart rate creeping upward, blood pressure readings trending above baseline, poor HRV scores
Adiposity and Hormonal Disruption
Park's prospective study of 43,722 women found that sleeping with artificial light (room light or television) was associated with 17% higher odds of gaining five or more kilograms over five years.[31] The mechanism is not caloric. It is hormonal. Scheer's forced misalignment data showed a 17% leptin reduction, meaning the satiety signal weakens when the circadian signal fails.[27] The body does not simply store more fat. It loses the hormonal brake that would normally prevent overconsumption.
weight gain despite unchanged diet, persistent late-night appetite, difficulty maintaining body composition
Cancer and Immune Dysregulation
Night shift work is classified as a Group 2A probable carcinogen by the IARC, with breast, prostate, colon, and rectal cancers implicated, a classification reflecting "strong" mechanistic evidence.[33] The specific epidemiology is less settled: Schernhammer's 2001 analysis of 78,562 nurses found that 30 or more years of rotating night shifts was associated with an RR of 1.36 for breast cancer (95% CI: 1.04–1.78), but a 2017 extended follow-up of the same cohort over 24 years found no significant association (HR = 0.95, 95% CI: 0.77–1.17).[32] The relationship between long-term night shift work and breast cancer risk remains an active area of investigation. Melatonin's antioxidant capacity, directly scavenging reactive oxygen species and upregulating SOD, catalase, and GPx, represents a plausible but not yet confirmed protective mechanism.[35] The nocturnal melatonin signal has been described as "the only circadian-driven anticancer signal identified in humans thus far."[4]
chronic immune suppression, slow wound healing, elevated inflammatory markers
05Protocol
A 4-Step Melatonin Signal Restoration Protocol
This protocol does not administer a sedative. It restores the light-darkness timing signal the suprachiasmatic nucleus requires to synchronise peripheral organ clocks and prevents modern artificial light from abolishing that signal before it can be generated.
The protocol, as a sequence.
Evening → Dusk onward → All 7 days → Travel
Time to Your DLMO
Take 0.5–1 mg immediate-release melatonin 3–5 hours before your target bedtime, not at bedtime. Estimate your DLMO as approximately 2 hours before the time you naturally feel drowsy on an unalarmed night.[20][26]
The phase-response curve dictates that melatonin taken in the early biological evening advances the clock; melatonin taken at the sleep onset window produces sedation but no phase shift. Cruz-Sanabria's dose-response meta-analysis confirmed that 3 hours before bed significantly outperforms 30 minutes before bed.[26]
Taking melatonin at bedtime. This is the dominant misuse pattern globally. It places the dose in the wrong PRC phase, producing mild drowsiness but zero circadian advance.
Dim Your Environment
Reduce all household lighting below ~10 lux in the 2–3 hours before target bedtime, candlelight level, not dimmer-switch level.[14][15]
Gooley's controlled crossover showed that 200 lux suppresses melatonin by >50%. Total irradiance reduction is the primary variable; spectrum filtering is secondary. The goal is to stop suppressing endogenous production before you supplement exogenous production.
Blue-light glasses without reducing total light intensity. Filtering wavelength while leaving brightness at 200 lux is a partial intervention that addresses the secondary variable while ignoring the primary one.
Fix Your Wake Time
Hold wake time within a 30–60 minute window across all seven days, including weekends.[27]
Weekend sleep-ins of 2–3 hours restart circadian misalignment every Monday morning, creating chronic social jet lag, a measurable weekly phase disruption.[6] Scheer's forced desynchrony data shows that metabolic consequences appear within days of misalignment onset. The weekend-to-weekday phase shift is not benign recovery; it is iatrogenic disruption.
Treating weekend late sleep as "recovery." The additional sleep hours do not offset the phase delay. They compound it by pushing the clock later and forcing a cold-start realignment every workweek.
Jet Lag Reset
On arrival night, take 0.5–5 mg melatonin at 22:00–midnight local destination time. Continue for 3–4 nights. Eastward travel shows the greatest benefit.[22]
The Cochrane review confirmed this protocol across 10 RCTs. The critical variable is timing to destination clock, not departure clock. Jet lag's objectivity as a stressor makes this the cleanest application of melatonin's chronobiotic action.
Taking melatonin on the flight at home-time bedtime, which delays rather than advances phase. Doses above 5 mg offer no additional phase-shift benefit and may cause next-day grogginess.
06Verdict
The verdict.
Bottom line
Melatonin is not something you take. It is something your body makes, and the first question is whether you are letting it.
The controlled evidence from 34 peer-reviewed sources converges on a single reframe: melatonin's clinical value is not in making you fall asleep seven minutes faster. It is in telling every organ in your body what time it is, and the gap between that function and how most people use the molecule is now the central problem in consumer sleep supplementation. Correctly timed at physiological doses, melatonin advances the circadian clock by over an hour. Taken at bedtime in pharmacological doses, it provides mild sedation with no phase shift. The molecule is the same. The timing is the variable. And the environment, 200 lux of ordinary room light that suppresses the endogenous signal by more than half, is the context that most supplement users have never been told to address.
The reframe is not academic. It changes what you buy, when you take it, and what you do to your light environment in the hours before sleep. A 0.5 mg dose taken 3 to 5 hours before bed, in a room dimmed below 10 lux, aligns with the strongest controlled evidence. A 10 mg dose taken at midnight under full room lighting contradicts virtually everything the evidence hierarchy establishes. Both patterns are legal, widely practised, and sold on the same pharmacy shelf. The difference is not preference. It is physiology.
The broader implication extends beyond supplementation. The body's timing architecture was not designed for 200-lux evenings, rotating shift schedules, or transcontinental travel. Restoring the melatonin pulse, whether through environmental control, correctly timed exogenous melatonin, or both, is not a wellness optimisation. It is the correction of a signal that modern life suppresses by default.
The science is not ambiguous. The evidence hierarchy is not contested. What remains is the gap between what the research shows and what most people do, a gap that seven minutes of sleep onset latency cannot close, but a correctly timed clock signal might.
No comparison figure runs here. The prose above does not resolve to one clean effect size to set against another, and this magazine does not manufacture a number to fill the space. The verdict stands on the evidence as written.
Clock signal, not sedative
The strongest controlled evidence establishes melatonin as a potent chronobiotic and a marginal hypnotic. Phase-shifting at physiological doses is robust and replicated; sedation at any dose is modest by independent meta-analytic estimate. The molecule's value is in its timing function, not its sedative side-effect.
Signal suppression compounds
Chronic melatonin signal disruption, from light exposure, mistiming, or age-related decline, produces cumulative metabolic, cardiovascular, and immunological costs that surface as clinical pathology over years. The body tolerates one bad night; it does not tolerate a permanently broken timing signal.
Timing over dosing
The highest-leverage intervention is not a higher dose. It is the correct dose at the correct circadian phase in a dim environment, restoring the conditions under which the endogenous signal can function and the exogenous supplement can extend it.
Put it to work
Where this science goes next on HPC
07Bibliography
The bibliography.
-
01
Journal
doi: 10.1001/jama.2021.23652
Trends in use of melatonin supplements among US adults, 1999–2018
-
02
Journal
doi: 10.1001/jamapediatrics.2023.4749
Characteristics of melatonin use among US children and adolescents
-
03
Journal
Notes from the field: emergency department visits for unsupervised pediatric melatonin ingestion, United States, 2019–2022
-
04
Journal
doi: 10.1016/j.scitotenv.2017.07.056
Health consequences of electric lighting practices in the modern world
-
05
Release
The 2017 Nobel Prize in Physiology or Medicine, Press Release
-
06
Journal
doi: 10.1016/S0140-6736(01)06108-6
Health in a 24-h society
-
07
Journal
Melatonin: fifty years of scientific journey from the discovery in bovine pineal gland to delineation of functions in human
-
08
Journal
doi: 10.1111/bph.14116
New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation
-
09
Journal
doi: 10.1016/j.neuchi.2015.03.002
Melatonin: physiological effects in humans
-
10
Review
doi: 10.1146/annurev-pharmtox-010814-124742
MT1 and MT2 melatonin receptors: a therapeutic perspective
-
11
Journal
doi: 10.1111/jpi.13011
Melatonin, melatonin receptors and sleep: moving beyond traditional views
-
12
Journal
doi: 10.1177/074873049701200507
Salivary melatonin as a circadian phase marker: validation and comparison to plasma melatonin
-
13
Journal
Melatonin shifts human circadian rhythms according to a phase-response curve
-
14
Journal
doi: 10.1210/jc.2010-2098
Exposure to room light before bedtime suppresses melatonin onset and shortens melatonin duration in humans
-
15
Journal
doi: 10.1210/jc.2003-030570
High sensitivity of the human circadian melatonin rhythm to resetting by short wavelength light
-
17
Journal
doi: 10.2174/1570159X14666161228122115
Melatonin: pharmacology, functions and therapeutic benefits
-
18
Journal
doi: 10.1056/NEJM199701163360306
Melatonin in humans
-
19
Chapter
Physiology of the pineal gland and melatonin. In K.R. Feingold et al. (Eds.), Endotext [Internet]. MDText.com. NCBI Bookshelf, NBK550972
-
20
RCT
doi: 10.1371/journal.pmed.1002587
Efficacy of melatonin with behavioural sleep-wake scheduling for delayed sleep-wake phase disorder: a double-blind, randomised clinical trial
-
21
Meta
doi: 10.1371/journal.pone.0063773
Meta-analysis: melatonin for the treatment of primary sleep disorders
-
22
Meta
doi: 10.1002/14651858.CD001520
Melatonin for the prevention and treatment of jet lag
-
24
Journal
doi: 10.1185/030079907X233098
Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years
-
25
Journal
Sleep-promoting effects of melatonin: at what dose, in whom, under what conditions, and by what mechanisms? Sleep, 20(10), 908–915
-
26
Meta
doi: 10.1111/jpi.12985
Optimizing the time and dose of melatonin as a sleep-promoting drug: systematic review of RCTs and dose-response meta-analysis
-
27
Journal
doi: 10.1073/pnas.0808180106
Adverse metabolic and cardiovascular consequences of circadian misalignment
-
28
Journal
doi: 10.2337/db13-1546
Circadian misalignment augments markers of insulin resistance and inflammation, independently of sleep loss
-
29
Journal
doi: 10.1073/pnas.1516953113
Circadian misalignment increases cardiovascular disease risk factors in humans
-
30
Journal
doi: 10.1073/pnas.2113290119
Light exposure during sleep impairs cardiometabolic function
-
31
Journal
doi: 10.1001/jamainternmed.2019.0571
Association of exposure to artificial light at night while sleeping with risk of obesity in women
-
32
Journal
doi: 10.1093/jnci/93.20.1563
Rotating night shifts and risk of breast cancer in women participating in the Nurses' Health Study
-
33
Journal
Night Shift Work. IARC Monographs on the Identification of Carcinogenic Hazards to Humans
-
35
Journal
doi: 10.1007/s12640-012-9337-4
Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes
-
37
Journal
doi: 10.5664/jcsm.6462
Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content
-
41
Journal
Pediatric melatonin ingestions, United States, 2012–2021
No entries match the current filter and search.
THE HAND-OFF — Performance Scan: find your limiting factor. Three minutes, 24 questions, six systems — and your answers never leave your device.
